Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03036124 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,744
- Enrollment target
NCT03036124: Completed Phase 3 study, sponsored by AstraZeneca.
NCT03036124 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 4,744 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (515% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03036124, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,744 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
Primary Outcome
Primary efficacy
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,744 participants |
| Start Date | 2017-02-08 |
| Est. Completion | 2019-07-17 |
| Phase | Phase 3 |
What the finished NCT03036124 record still lists
NCT03036124 is an interventional study that assigns participants to a tested intervention. Its 4,744 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (515% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03036124 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03036124 about?
NCT03036124 is a clinical study titled "Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure". The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
What is the current status of trial NCT03036124?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,744 participants. The study started on 2017-02-08. Estimated completion is 2019-07-17.
What interventions are being tested in trial NCT03036124?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT03036124?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03036124's enrollment target sits among peer trials
4,744 54th of 2000 higher than 1,947 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04371900 · 4,700 participants · NA
Michigan Contraceptive Access, Research, and Evaluation Study Children: Phase 1
- NCT05486572 · 4,700 participants · NA
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- NCT06888388 · 4,700 participants
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
- NCT01719055 · 4,800 participants
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI